Sanofi’s $2.2 billion acquisition of Dynavax Technologies Corporation in late 2025 secured not only the two-dose hepatitis B vaccine HEPLISAV-B, but also the proprietary adjuvant that underpins it: CpG 1018, a toll-like receptor 9 (TLR9) agonist. As 2026 begins, attention is turning from the vaccine products themselves to the immune-modulating platform that powers them.
TLR9 agonists are increasingly seen as strategic assets in vaccine design—especially in the context of adult immunization, where dose minimization, co-formulation flexibility, and enhanced durability of protection are rising priorities. Sanofi’s bet on CpG 1018 puts it in a position to explore more advanced combination vaccine strategies, particularly in chronic viral infections, respiratory pathogens, and emerging zoonotic threats.
While the industry is still early in validating synthetic TLR agonists in broad applications, a growing body of evidence suggests they may enable the next wave of vaccine innovation—moving beyond aluminum salts and oil-in-water emulsions to more targeted and tunable immune engagement.
Why CpG 1018 stands out in the adjuvant landscape
Dynavax’s CpG 1018 is a short synthetic oligodeoxynucleotide sequence that mimics bacterial DNA motifs and stimulates immune responses through TLR9, a receptor found primarily in plasmacytoid dendritic cells and B cells. When used as an adjuvant, CpG 1018 accelerates and amplifies the immune response to a co-administered antigen, making it particularly useful in populations with reduced immune responsiveness.
The most prominent application to date has been in HEPLISAV-B, which showed both improved seroprotection and reduced time-to-immunity compared to traditional alum-adjuvanted hepatitis B vaccines. This performance has spurred interest in CpG 1018’s potential beyond monovalent formulations. Notably, Dynavax has investigated its use in pandemic preparedness, including COVID-19, and preclinical models of influenza, RSV, and herpes zoster.
Sanofi’s acquisition brings this adjuvant platform in-house, where it could be deployed across internal and partnered programs. Given Sanofi’s ongoing investments in mRNA, protein subunit, and vector-based vaccines, CpG 1018 may serve as a modular component—one that can be fine-tuned to meet specific immunological or demographic needs.
How TLR9 agonists differ from traditional adjuvants
Traditional vaccine adjuvants like aluminum hydroxide primarily act as antigen depots and slow-release systems, passively enhancing immune responses over time. In contrast, synthetic TLR9 agonists actively trigger specific innate immune pathways, leading to more rapid and targeted activation of adaptive responses.
This difference is more than immunological nuance. It translates into practical advantages in durability, speed of protection, and potentially reduced reactogenicity when paired correctly. For adult and elderly populations—where immunosenescence weakens vaccine responses—this targeted innate stimulation may prove essential for achieving protective titers without resorting to additional doses or booster programs.
Additionally, TLR9-based adjuvants are chemically defined and synthetically manufactured, offering manufacturing scalability and consistency that are critical in global vaccine supply chains. Their stability profiles also make them more amenable to lyophilization and non-cold chain formulations—important features for combination vaccines and pandemic deployment scenarios.
What TLR9 platforms could enable in combination vaccines
One of the most promising use cases for CpG 1018 and similar TLR9 agonists lies in combination vaccine design. By offering stronger immune activation from a single antigen presentation, these adjuvants may make it possible to combine more antigens into a single injection without immune interference or dilution of response.
This could be especially useful in adult populations that require catch-up vaccination for multiple conditions. A hepatitis B–shingles–RSV combination, for example, might become viable if adjuvant support can ensure non-overlapping immune memory and controlled reactogenicity. Likewise, combination travel vaccines or chronic disease-related bundles (such as hepatitis B and pneumococcal for diabetics) could be reformulated with more durable and rapid protection.
The use of TLR9 agonists also opens the door for more experimental formulations, such as neoantigen cancer vaccines, HIV immunogens, and immunotherapeutic prophylaxis in high-risk exposure scenarios. Although such applications remain early in development, the regulatory precedent set by HEPLISAV-B gives CpG 1018 an advantage in regulatory familiarity.
What scientific and regulatory hurdles still remain
Despite the growing interest, TLR9 adjuvants are not without challenges. Their mechanism of action, while precise, can also generate systemic inflammatory signals that must be carefully managed in formulation. Adjuvant–antigen pairing needs rigorous optimization to avoid overactivation or unintended immune suppression.
Moreover, while HEPLISAV-B offers proof of concept, broader deployment of CpG 1018 in other vaccines will likely require full clinical validation in each use case. Unlike antigens, adjuvants cannot be assumed to be interchangeable across diseases or platforms. For Sanofi to make CpG 1018 a cross-portfolio asset, it will need to invest in robust translational immunology programs to define dose ranges, biomarkers of response, and patient stratification criteria.
Regulatory authorities have historically taken a conservative stance on novel adjuvants. The pathway for approving vaccines with previously untested adjuvants is longer and often requires post-marketing commitments. While CpG 1018 has an established record in the United States and European Union, its use in co-formulated or combo vaccines may still face scrutiny.
There is also competitive pressure. Other adjuvant systems—such as AS01 (used in Shingrix), Matrix-M (used in Novavax’s COVID-19 vaccine), and proprietary oil-in-water emulsions—are being optimized in parallel. Companies like GSK and Pfizer continue to refine their own adjuvant platforms, aiming for balance between potency, tolerability, and manufacturing scalability.
Why Sanofi’s platform acquisition may have long-term implications
The significance of Sanofi acquiring CpG 1018 is not just in its immediate application to hepatitis B or shingles. It marks a platform expansion—an acquisition of an immune tuning engine that can be applied across Sanofi’s internal development programs. With respiratory, travel, and aging-related diseases becoming core to adult immunization strategies, this gives Sanofi a toolset to design vaccines that are more targeted, durable, and commercially differentiated.
It also puts Sanofi in a stronger licensing position. Should the company validate CpG 1018 in new indications, it could offer the adjuvant to partners developing vaccines that lack strong innate immune activation. This could extend Sanofi’s influence beyond its own pipeline, similar to how adjuvant platforms like AS03 or MF59 have been out-licensed by their developers.
As 2026 unfolds, investors and clinicians will be watching for signs that Sanofi is integrating CpG 1018 into broader development workflows. Clinical trial launches, new formulation patents, or even early data readouts involving the shingles candidate Z-1018 could offer visibility into the platform’s next phase of impact.
How Sanofi’s CpG 1018 platform could reshape vaccine formulation in 2026 added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →